CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0511 (clinicaltrials.gov NCT No: NCT01254890)
Title:PHASE I/II STUDY OF SORAFENIB AND 5-AZACITIDINE FOR THE TREATMENT OF PATIENTS WITH REFRACTORY OR RELAPSED ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME (MDS) - (VZ-MDS-PI-0227)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:5-Azacytidine; Sorafenib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if 5-azacitidine and
sorafenib can control the disease in patients with AML or MDS. The safety of
this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:5-Azacytidine
Sorafenib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Bayer/Onyx
Celgene
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults